Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02481154
Title	Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Institut de Recherches Internationales Servier
Indications	high grade glioma Advanced Solid Tumor
Therapies	Vorasidenib
Age Groups:	adult \| senior
Covered Countries	USA